Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF™ Therapy at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)


News provided by

Novocure

18 Nov, 2013, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

-- Neuro-Oncology experts from around the world will gather in San Francisco where data supporting the role of Tumor Treating Fields (TTFields) in treating recurrent glioblastoma brain tumors will be presented

ST. HELIER, Jersey, Nov. 18, 2013 /PRNewswire/ -- Novocure announced today that 15 preclinical and clinical abstracts describing the latest aspects of NovoTTF™ Therapy will be presented at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO), which is being held in conjunction with the 18th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in San Francisco, California from November 21-24, 2013.

"We are pleased to announce that multiple abstracts evaluating NovoTTF Therapy and its role in the treatment of brain cancer will be presented at this very prestigious medical congress. The majority of these abstracts are by renowned neuro-oncology experts from around the globe. Collectively, the growing body of evidence further supports NovoTTF Therapy in the treatment of recurrent glioblastoma and further elucidates the mechanisms of action of NovoTTF Therapy as an anti-cancer treatment," said Eilon Kirson, M.D., Ph.D., Novocure's Chief Science Officer and Head of Research and Development.

In addition to the data presentations, Novocure has provided an unrestricted grant for a continuing medical educational program on central nervous system tumors that will be held on Thursday, November 21 at 7:30pm PT. More information about this program including registration information can be found by accessing www.researchtopractice.com.

Novocure is also sponsoring a lunch symposium on Saturday, November 23 at 12:00pm that will focus on practical considerations for NovoTTF Therapy in the treatment of recurrent Glioblastoma.

Title: NovoTTF Therapy:  A New Frontier in Recurrent Glioblastoma

Faculty:  Steven Toms, MD (Geisinger Medical System), Ashley Sumrall, MD (Levine Cancer Center and Eilon Kirson, MD, PhD (Novocure)

Location: San Francisco Marriott Marquis Hotel, Yerba Buena 12:00 – 1:00 PM

Detailed information about the data presentations are listed below:

Poster sessions on Friday, November 22, 7-9pm:

Phase III trial of Tumor Treating Fields (TTFields) together with temozolomide (TMZ) compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM). Presenter: Ori Farber, Novocure, Israel.  Poster: MR-008.

Use of NovoTTF-100A™ in heavily pre-treated patients with relapsed high grade glioma: a retrospective chart review. Presenter: Ashley Sumrall, Carolinas Healthcare System, Medical University of South Carolina USA.  Poster: MR-032,

A phase II randomized study of TTFields therapy versus supportive care in non-small cell lung cancer (NSCLC) patients with 1-3 brain metastases (BM) following stereotactic radio-surgery (SRS).  Presenter: Uri Weinberg, Novocure, Switzerland.  Poster: MR-036.

Radiographic response of an incidental meningioma in a patient with glioblastoma on NovoTTF therapy.  Presenter: Lauren Schaff, Columbia University, USA.  Poster: NO-006.

Tumor Treating Fields (TTFields) in recurrent GBM. An updated subgroup analysis of the Phase III data.  Presenter: Andrew Kanner, Tel Aviv Sourasky Medical Center, Israel.  Poster: NO-065.

The effect of field strength on GBM response in patients treated with Novocure-TTF. Presenter: Scott Turner, Geisinger Medical Center, USA.   Poster: NO-134.

Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure.   Presenter: Eric T. Wong, Beth Israel Deaconess Medical Center, USA.  Poster: NO-146.

Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas.  Presenter: Grace Elzinga, Beth Israel Deaconess Medical Center, USA.  Poster: NO-147.

Poster sessions on Saturday, November 23, 5-7pm:

Alternating electric fields (TTFields) inhibit DNA damage repair response in cancer cell lines.  Presenter: Moshe Giladi, Novocure Ltd., Israel.   Poster: ET-028.

Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in-vitro.  Presenter: Moshe Giladi, Novocure Ltd., Israel.  Poster: ET-029.

Analysis of combination of Tumor Treating Fields (TTFields) with radiotherapy in non-small cell lung cancer.   Presenter: Katarzyna Zielinska-Chomej, Karolinska Institutet, Sweden.  Poster: ET-033.

Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death.   Presenter: Sze Xian Lee, Beth Israel Deaconess Medical Center, USA.  Poster: IR-022.

Meta-analysis of cancer cell line genomes based on their response to alternating electric fields (TTFields).   Presenter: Moshe Giladi, Novocure Ltd. Israel.  Poster: MP-005.

Electric fields for the treatment of glioblastomas: a modeling study.   Presenter: Cornelia Wenger, University of Lisbon, Portugal.  Poster: TM-028.

Dermatologic event characteristics and management with the NovoTTF-100A System, a novel antimitotic device for the treatment of recurrent glioblastoma.   Presenter: Mario Lacouture, Memorial Sloan-Kettering Cancer Center, USA.  Poster: SM-014.

About The NovoTTF-100A System
The NovoTTF-100A System is a wearable, non-invasive anti-mitotic device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow or reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.The portable delivery system creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death. The NovoTTF-100A System, a NovoTTF Therapy delivery system, has received marketing approval in the United States (U.S.) and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel.

Approved Indication
The U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following confirmed disease recurrence. The device is intended to be used as monotherapy as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.

Full prescribing information is available at NovoTTFTherapy.com or by calling toll free 1-855-281-9301.NovoTTF Therapy is experimental for the treatment of newly diagnosed glioblastoma. Limited by law to investigational use only.  NovoTTF Therapy is not approved for the treatment of brain metastases, meningiomas or NSCLC. The safety and efficacy of NovoTTF Therapy for these indications has not been established.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure Inc., Novocure's U .S. subsidiary, has operations in New York, NY and Portsmouth, NH. Novocure's research center is located in Haifa, Israel. For additional information about the company, please visit www.novocure.com.

Contact:
Peter Melnyk, Novocure
pmelnyk@novocure.com
+1-(212) 767-7534

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.